Ypsomed Holding AG Logo

Ypsomed Holding AG

0QLQ.L

(0.2)
Stock Price

419,00 CHF

10.65% ROA

12.75% ROE

57.58x PER

Market Cap.

38.200.942,00 CHF

0% DER

0.42% Yield

14.24% NPM

Ypsomed Holding AG Stock Analysis

Ypsomed Holding AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ypsomed Holding AG Fundamental Stock Analysis
# Analysis Rating
1 Dividend Growth

With a history of consistent dividend increases over the last three years, the company has proven to be a reliable choice for investors seeking reliable income.

2 ROE

Unidentified ROE

3 ROA

Unidentified ROA

4 PBV

Unidentified ROA

5 DER

Unidentified DER

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

Unidentified Graham Number

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Ypsomed Holding AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ypsomed Holding AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Ypsomed Holding AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ypsomed Holding AG Revenue
Year Revenue Growth
2012 244.565.000
2013 276.257.000 11.47%
2014 306.632.000 9.91%
2015 336.922.000 8.99%
2016 389.555.000 13.51%
2017 466.119.000 16.43%
2018 453.765.000 -2.72%
2019 394.264.000 -15.09%
2020 403.656.000 2.33%
2021 464.841.000 13.16%
2022 497.460.000 6.56%
2023 510.780.000 2.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ypsomed Holding AG Research and Development Expenses
Year Research and Development Expenses Growth
2012 26.979.000
2013 27.712.000 2.65%
2014 33.460.000 17.18%
2015 32.256.999 -3.73%
2016 38.664.000 16.57%
2017 40.551.000 4.65%
2018 56.838.000 28.66%
2019 18.247.000 -211.49%
2020 16.788.000 -8.69%
2021 21.954.000 23.53%
2022 28.953.000 24.17%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ypsomed Holding AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 12.752.000
2013 13.884.000 8.15%
2014 15.530.000 10.6%
2015 15.782.000 1.6%
2016 18.154.000 13.07%
2017 20.720.000 12.38%
2018 24.070.000 13.92%
2019 21.981.000 -9.5%
2020 21.095.000 -4.2%
2021 23.029.000 8.4%
2022 26.219.000 12.17%
2023 27.342.000 4.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ypsomed Holding AG EBITDA
Year EBITDA Growth
2012 29.608.000
2013 35.322.000 16.18%
2014 47.413.000 25.5%
2015 64.644.000 26.66%
2016 75.193.000 14.03%
2017 80.672.000 6.79%
2018 98.995.000 18.51%
2019 39.888.000 -148.18%
2020 43.259.000 7.79%
2021 68.883.000 37.2%
2022 87.554.000 21.33%
2023 151.664.000 42.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ypsomed Holding AG Gross Profit
Year Gross Profit Growth
2012 57.075.000
2013 70.526.000 19.07%
2014 85.850.000 17.85%
2015 103.187.000 16.8%
2016 125.479.000 17.77%
2017 139.826.000 10.26%
2018 156.414.000 10.61%
2019 90.974.000 -71.93%
2020 94.828.000 4.06%
2021 113.817.000 16.68%
2022 140.592.000 19.04%
2023 175.636.000 19.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ypsomed Holding AG Net Profit
Year Net Profit Growth
2012 1.646.000
2013 13.608.000 87.9%
2014 19.395.000 29.84%
2015 35.812.000 45.84%
2016 46.247.000 22.56%
2017 52.060.000 11.17%
2018 60.136.000 13.43%
2019 11.734.000 -412.49%
2020 5.811.000 -101.93%
2021 23.105.000 74.85%
2022 51.275.000 54.94%
2023 73.158.000 29.91%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ypsomed Holding AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 1 100%
2014 2 0%
2015 3 50%
2016 4 33.33%
2017 4 25%
2018 5 0%
2019 1 0%
2020 0 0%
2021 2 100%
2022 4 66.67%
2023 5 40%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ypsomed Holding AG Free Cashflow
Year Free Cashflow Growth
2012 -777.000
2013 22.676.000 103.43%
2014 24.169.000 6.18%
2015 51.533.000 53.1%
2016 47.582.000 -8.3%
2017 2.241.000 -2023.25%
2018 -46.944.000 104.77%
2019 -27.661.000 -69.71%
2020 26.644.000 203.82%
2021 34.114.000 21.9%
2022 30.653.000 -11.29%
2023 11.661.500 -162.86%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ypsomed Holding AG Operating Cashflow
Year Operating Cashflow Growth
2012 15.168.000
2013 41.206.000 63.19%
2014 41.381.000 0.42%
2015 76.687.000 46.04%
2016 75.064.000 -2.16%
2017 53.269.000 -40.91%
2018 59.859.000 11.01%
2019 49.089.000 -21.94%
2020 85.828.000 42.81%
2021 85.706.000 -0.14%
2022 129.531.000 33.83%
2023 36.716.000 -252.79%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ypsomed Holding AG Capital Expenditure
Year Capital Expenditure Growth
2012 15.945.000
2013 18.530.000 13.95%
2014 17.212.000 -7.66%
2015 25.154.000 31.57%
2016 27.482.000 8.47%
2017 51.028.000 46.14%
2018 106.803.000 52.22%
2019 76.750.000 -39.16%
2020 59.184.000 -29.68%
2021 51.592.000 -14.72%
2022 98.878.000 47.82%
2023 25.054.500 -294.65%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ypsomed Holding AG Equity
Year Equity Growth
2012 217.375.000
2013 228.162.000 4.73%
2014 240.637.000 5.18%
2015 267.836.000 10.16%
2016 301.796.000 11.25%
2017 341.542.000 11.64%
2018 378.804.000 9.84%
2019 377.659.000 -0.3%
2020 395.385.000 4.48%
2021 392.540.000 -0.72%
2022 562.333.000 30.19%
2023 573.692.000 1.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ypsomed Holding AG Assets
Year Assets Growth
2012 341.793.000
2013 354.528.000 3.59%
2014 361.211.000 1.85%
2015 388.871.000 7.11%
2016 421.801.000 7.81%
2017 500.239.000 15.68%
2018 587.748.000 14.89%
2019 678.240.000 13.34%
2020 717.683.000 5.5%
2021 756.910.000 5.18%
2022 861.879.000 12.18%
2023 936.683.000 7.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ypsomed Holding AG Liabilities
Year Liabilities Growth
2012 124.418.000
2013 126.366.000 1.54%
2014 120.574.000 -4.8%
2015 121.035.000 0.38%
2016 120.005.000 -0.86%
2017 158.697.000 24.38%
2018 208.944.000 24.05%
2019 300.581.000 30.49%
2020 322.298.000 6.74%
2021 364.370.000 11.55%
2022 299.546.000 -21.64%
2023 362.991.000 17.48%

Ypsomed Holding AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
37.26
Net Income per Share
5.31
Price to Earning Ratio
57.58x
Price To Sales Ratio
0.08x
POCF Ratio
31.3
PFCF Ratio
0.97
Price to Book Ratio
7.27
EV to Sales
0
EV Over EBITDA
0.02
EV to Operating CashFlow
0.01
EV to FreeCashFlow
0.05
Earnings Yield
0.02
FreeCashFlow Yield
1.03
Market Cap
0,04 Bil.
Enterprise Value
0,00 Bil.
Graham Number
70.84
Graham NetNet
-16.13

Income Statement Metrics

Net Income per Share
5.31
Income Quality
1.84
ROE
0.13
Return On Assets
0.08
Return On Capital Employed
0.09
Net Income per EBT
0.93
EBT Per Ebit
1.36
Ebit per Revenue
0.11
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.32
Operating Profit Margin
0.11
Pretax Profit Margin
0.15
Net Profit Margin
0.14

Dividends

Dividend Yield
0
Dividend Yield %
0.42
Payout Ratio
0.25
Dividend Per Share
1.27

Operating Metrics

Operating Cashflow per Share
9.76
Free CashFlow per Share
2.88
Capex to Operating CashFlow
-0.71
Capex to Revenue
-0.18
Capex to Depreciation
-2.19
Return on Invested Capital
0.1
Return on Tangible Assets
0.11
Days Sales Outstanding
68.67
Days Payables Outstanding
25.98
Days of Inventory on Hand
73.4
Receivables Turnover
5.32
Payables Turnover
14.05
Inventory Turnover
4.97
Capex per Share
-6.89

Balance Sheet

Cash per Share
2,67
Book Value per Share
42,03
Tangible Book Value per Share
23.21
Shareholders Equity per Share
42.03
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.34
Current Ratio
0.77
Tangible Asset Value
0,32 Bil.
Net Current Asset Value
-0,11 Bil.
Invested Capital
0
Working Capital
-0,07 Bil.
Intangibles to Total Assets
0.27
Average Receivables
0,10 Bil.
Average Payables
0,02 Bil.
Average Inventory
69506000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ypsomed Holding AG Dividends
Year Dividends Growth
2016 1
2017 1 0%
2022 1 0%
2023 1 100%

Ypsomed Holding AG Profile

About Ypsomed Holding AG

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

CEO
Mr. Simon Michel
Employee
2.200
Address
Brunnmattstrasse 6
Burgdorf, 3401

Ypsomed Holding AG Executives & BODs

Ypsomed Holding AG Executives & BODs
# Name Age
1 Mr. Sebastien Delarive
Chief Business Officer of Ypsomed Diabetes Care
70
2 Ms. Ulrike Bauer
Chief Business Officer of Ypsomed Delivery Systems
70
3 Mr. Michael Zaugg
Chief Corporate Officer
70
4 Mr. Simon Michel
Member of the Board
70
5 Dr. Nicolas Meyer
Chief Legal Officer
70
6 Mr. Frank Mengis
Chief Operating Officer
70
7 Mr. Niklaus Ramseier
Chief Financial Officer
70
8 Thomas Kutt
Head of Investor Relations
70

Ypsomed Holding AG Competitors